# Ardelyx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ardelyx

- Industry: Pharmaceuticals
- Headquarters: Fremont, US
- Website: www.ardelyx.com
- Total disclosed funding: $44M
- Latest round: Series B (Jun 23, 2011)
- Investors on record: 3

## About

Ardelyx, Inc. is a biotechnology company focused on developing innovative medicines for chronic kidney disease and gastrointestinal disorders, aiming to meet significant unmet medical needs with its unique therapeutic solutions.Founded in 2007 in Fremont, US, Ardelyx, Inc. specializes in the development of therapeutics for chronic kidney disease and gastrointestinal disorders. The company raised USD 27.5 mn in its latest funding round of Venture Debt, bringing the total amount raised to USD 20 mn. The current CEO is Mike Raab. The company has completed a total of 10 deals, with the most recent deal dated June 19, 2014. Ardelyx has not undergone any significant pivots or changes in its operations.Ardelyx, Inc. develops first-in-class medicines focused on chronic kidney disease and gastrointestinal disorders, including treatments for hyperphosphatemia and irritable bowel syndrome with constipation (IBS-C). Their flagship product, IBSRELA® (tenapanor), addresses the critical needs of patients suffering from IBS-C, while the products are distributed across various markets, including the United States and select international regions.In the most recent fiscal year 2024, Ardelyx reported revenue of USD 319,196 and an EBITDA of USD -25,887. The company generates revenue through the commercialization of its proprietary medicines, primarily through transactions with healthcare providers and pharmacy systems.Ardelyx plans to utilize the recent funding from its June 2014 deal to advance its clinical-stage product, RDX5791, along with two preclinical products, RDX002 for chronic kidney disease and RDX009 for type 2 diabetes. The company is also looking to expand into new markets, focusing on broader distribution in the United States and targeting select international regions to enhance accessibility to its products.

## Funding rounds

- Series B, Jun 23, 2011, $18M — New Enterprise Associates, Presidio Partners, Amgen Ventures
- Series A, Jun 7, 2008, $26M — New Enterprise Associates, Presidio Partners

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series A, Series B
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series B